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Prostacyclin Analogues 
Sir, 
We read with interest the recent reports by Thomson et 
al. 1 and Sayers et al. 2 concerning the effects of the 
prostacyclin analogue iloprost on leukocyte adhesion 
and smooth muscle cells of vein grafts. Prostacyclin 
may have a role in the regulation of cell growth in the 
vascular wall, 3 and reduced prostacyclin production 
from damaged vein graft endothelium is thought o 
contribute to smooth muscle cell proliferation, the 
principal cause of late graft failure. 4These data have 
been extrapolated to suggest hat prostacyclin ana- 
logues might be useful in minimising intimal hyper- 
plasia in vein grafts. 
We tested this hypothesis in an established organ 
culture model of human saphenous vein 5 using 
Cicaprost (Schering Health Care Ltd, U.K.), a stable 
prostacyclin analogue. Segments of freshly isolated 
saphenous vein harvested from eight patients under- 
going elective coronary artery bypass surgery were 
obtained. Vein was transferred to the laboratory at 
room temperature in Hepes buffered RPMI 1640 
culture medium supplemented with penicillin (100 
/xg/ml), streptomycin (100 units/ml), amphotericin 
(2.5 /xg/ml), gentamycin (2.5 /~g/ml), glutamine 
(2mM). Each vein segment was then split into three 
equal sections (one for control and two to test) and 
cultured as previously described. 6 
Briefly, excess fat and adventitial tissue were dis- 
sected from the vessel which was then opened out 
along its upper aspect and pinned, intimal surface 
uppermost, onto a polyester gauze support resting on 
sylgard resin set in the base of a glass Petri dish. Vein 
segments were washed several times with medium 
and then cultured in RPMI 1640 culture medium 
containing sodium bicarbonate (2.0 g/l) and 30% 
foetal calf serum (Northumbria Biologicals, North- 
umberland, U.K.). Cultures were maintained for 14 
days in a humidified atmosphere with 5% (v/v) CO2 
in air. The culture medium was replaced every 2-3 
days. Parallel cultures were set up with the addition of 
Table 1. Data expressed as mean _+ SE (n=8) 
ATP 
concentration Intimal [3H] thymidine 
(nmol/g wet thickness uptake 
weight) 0xm) (DPM//zg DNA) 
Freshly isolated vein 320+135 0 0 
(day 0) 
Freshly isolated vein 310+78 34.2_+10.1 752_+168 
(day 14) 
Freshly isolated vein+ 296+41 38.9_+1.6 605+68 
Cicoprost [104 M] 
(day 14) 
Freshly isolated vein+ 356+125 29.6_+7.1 585_+98 
Cicoprost [10 .9 M] 
(day 14) 
Cicaprost at two concentrations (10 4 M and 10 -9 M). 
Cultures were pulse labelled with [3H] thymidine 
(Amersham Int., U.K.) for the last 24 h of the 14 day 
culture period. 
Tissue viability as defined by adenosine triphos- 
phate (ATP) concentration was measured in perchloric 
acid extracts of vein using HPLC. 6 Intimal thickening 
was assessed in 5/xm histological transverse paraffin 
sections tained with Alcian Blue/Millers Elastic/Van 
Gieson at 20 equidistant points along the section 
length using an image analyser (SeeScan, Cambridge, 
U.K.). Cell proliferation was quantified by 3H] thymi- 
dine incorporation and autoradiography. 
ATP concentration ( mol/g wet weight) was main- 
tained throughout the culture period in the freshly 
isolated veins and in the presence of Cicaprost. There 
were no significant differences in the degree of intimal 
thickening or cell proliferation i  veins cultured with 
either concentration of Cicaprost when compared to 
controls using paired data in a Student -test (Table 1). 
Autoradiography also showed no significant differ- 
ence in the number of 3H] thymidine labelled cells/ 
mm section length in the neointima. These data show 
that Cicaprost does not inhibit smooth muscle cell 
proliferation and neointimal formation in the human 
saphenous vein organ culture when used at concentra- 
tions of 10 .8 M and 10 -9 M. 
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There is ample evidence that, during surgical 
preparation, the loss of endothelial cells in the 
saphenous vein and impairment of their ability to 
produce prostacyclin and endothelium-derived r lax- 
ing factor promote platelet and leukocyte adhesion, 7 
and result in an early occlusion of 8-18% of grafts in 
the first month following surgeryJ The recently 
reported improvement in vein graft patency at 1 
month in man, with the topical application of prosta- 
cyclin analogues, 9 is likely to be due to its ability to 
counteract these effects by inhibiting platelet and 
leukocyte activation, aggregation and adhesion, and 
also improving raft flow, all of which have been well 
documentedJ "1°-12 Vein grafts that remain patent 
following this initial period experience a predictable 
and progressive intimal hyperplasia, long after the 
restoration of a morphologically intact endothelium 
and the termination of platelet and leucocyte adhe- 
sion. 13"14 This intimal thickening is caused by the 
proliferation and migration of vascular smooth muscle 
cells from the media, and results in late occlusions of 
saphenous vein grafts. In this stud~ we were not able 
to show any effect of Cicaprost on smooth muscle 
proliferation or intimal hyperplasia, we therefore 
conclude that it may not have any benefit in prevent- 
ing late saphenous vein graft failure. 
M.B. Izzat, T. Taylor, C.M. Holt and G.D. Angelini 
Bristol, U.K. 
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Femoral Osteochondroma 
Sir, 
I have read with interest he case reported by Fox et 
alJ about femoral artery occlusion secondary to a 
benign osteochondroma of the femur. Certainl~ inter- 
mittent claudication in young patients is extremely 
uncommon and unlikely to be atherosclerotic n
origin. Thorough investigation is warranted although 
I am not sure MRI added much information to the case 
described. 
Apart from arterial problems these patients may 
present with venous thrombosis--I have described a 
similar case of a 44-year-old man with a femoral 
metaphysis osteochondroma presenting with a spon- 
taneous DVT 3 years prior to the onset of occlusive 
arterial symptoms. 2 Plain radiography and colour 
flow Duplex were sufficient to diagnose the problem. 
Arteriography was necessary to determine the state of 
the distal vasculature - -  all 3 vessels were occluded 
secondary to microemboli. The case described by Fox 
et al. was fortunate in being diagnosed early, before 
distal microemboli caused further problems. 
In summar39 as stated by Fox et al. any young 
person presenting with symptoms and signs of arterial 
disease or spontaneous DVT warrants full investiga- 
tion. I would suggest plain radiograph~ colour flow 
Duplex and arteriography. 
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